Codo, P; Eigentler, T; Heinzerling, L; Krauss, J; Weishaupt, C; Ochsenreither, S; Lebbe, C; Mohr, P; Oliva, M; Oberoi, H; Terheyden, P; Perez, JT; Bauernfeind, FG; Fluck, M; Richtig, E; Soria, A; Gonzalez, M; Funkner, F; Wengenmayer, P; Vahrenhorst, D; Seibel, T; Quintini, G; Schmitt-Bormann, B; Scheel, B; Falk, M; Gnad-Vogt, U.
IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL
J IMMUNOTHER CANCER. 2021; 9: A502-A502.
Doi: 10.1136/jitc-2021-SITC2021.473
Web of Science
FullText
FullText_MUG